Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70

被引:42
作者
Nelson, MR [1 ]
Liew, D
Bertram, M
Vos, T
机构
[1] Univ Tasmania, Sch Med, Discipline Gen Practice, Hobart, Tas 7001, Australia
[2] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[3] WHO, CH-1211 Geneva, Switzerland
[4] Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia
来源
BMJ-BRITISH MEDICAL JOURNAL | 2005年 / 330卷 / 7503期
关键词
D O I
10.1136/bmj.38456.676806.8F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the routine use of low dose aspirin in people aged ! 70 without overt cardiovascular disease. Design Epidemiological modelling in a hypothetical population. Setting Reference populations of men and women in the year 2000 from the state of Victoria, Australia. Subjects 10 000 men and 10 000 women aged 70-74 with no cardiovascular disease. Main outcome measures First ever myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived. Results The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (- 389 in men, - 321 in women) and ischaemic stroke (- 19 in men and - 35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding. The results in health adjusted years of life lived (which take into account length and quality of life) are equivocal for aspirin causing net harm or net benefit. Conclusion Epidemiological modelling suggests that any benefits of low dose aspirin on risk of cardiovascular disease in people aged ! 70 are offset by adverse events. These findings are tempered by wide confidence intervals, indicating that the overall outcome could be beneficial or adverse.
引用
收藏
页码:1306 / 1308A
页数:4
相关论文
共 31 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   Nonsteroidal anti-inflammatory drugs and cancer prevention [J].
Baron, JA ;
Sandler, RS .
ANNUAL REVIEW OF MEDICINE, 2000, 51 :511-523
[3]   Prevalence of stroke and stroke-related disability - Estimates from the Auckland stroke studies [J].
Bonita, R ;
Solomon, N ;
Broad, JB .
STROKE, 1997, 28 (10) :1898-1902
[4]   Handling uncertainty in cost-effectiveness models [J].
Briggs, AH .
PHARMACOECONOMICS, 2000, 17 (05) :479-500
[5]   Primary and subsequent coronary risk appraisal: New results from The Framingham Study [J].
D'Agostino, RB ;
Russell, MW ;
Huse, DM ;
Ellison, RC ;
Silbershatz, H ;
Wilson, PWF ;
Hartz, SC .
AMERICAN HEART JOURNAL, 2000, 139 (02) :272-281
[6]  
*DEP HUM SERV VICT, 2000, VICT ADM EV DAT
[7]   The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
Cameron, AJ ;
Shaw, J ;
de Courten, M ;
Jolley, D ;
McCarty, DJ .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 57 (02) :119-129
[8]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[9]   Aspirin for the primary prevention of stroke and other major vascular events - Meta-analysis and hypotheses [J].
Hart, RG ;
Halperin, JL ;
McBride, R ;
Benavente, O ;
Man-Son-Hing, M ;
Kronmal, RA .
ARCHIVES OF NEUROLOGY, 2000, 57 (03) :326-332
[10]   Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force [J].
Hayden, M ;
Pignone, M ;
Phillips, C ;
Mulrow, C .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :161-172